Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

The clinical significance… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.

Artikel i vetenskaplig tidskrift
Författare Alba Corell
Sandra Ferreyra Vega
Nickoleta Hoefling
Louise Carstam
Anja Smits
Thomas Olsson Bontell
Isabella Björkman-Burtscher
Helena Carén
Asgeir Store Jakola
Publicerad i BMC cancer
Volym 20
Nummer/häfte 1
Sidor 450
ISSN 1471-2407
Publiceringsår 2020
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för fysiologi
Sahlgrenska Cancer Center
Institutionen för biomedicin, avdelningen för laboratoriemedicin
Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap
Institutionen för kliniska vetenskaper, Avdelningen för radiologi
Sidor 450
Språk en
Länkar dx.doi.org/10.1186/s12885-020-06951...
www.ncbi.nlm.nih.gov/entrez/query.f...
Ämnesord Astrocytoma, Biomarkers, Decision making, prognosis, Oligodendroglioma
Ämneskategorier Neurokirurgi, Diagnostisk radiologi, Neurologi, Cancer och onkologi

Sammanfattning

The T2-FLAIR mismatch sign is an imaging finding highly suggestive of isocitrate dehydrogenase mutated (IDH-mut) 1p19q non-codeleted (non-codel) gliomas (astrocytomas). In previous studies, it has shown excellent specificity but limited sensitivity for IDH-mut astrocytomas. Whether the mismatch sign is a marker of a clinically relevant subtype of IDH-mut astrocytomas is unknown.We included histopathologically verified supratentorial lower-grade gliomas (LGG) WHO grade II-III retrospectively during the period 2010-2016. In the period 2017-2018, patients with suspected LGG radiologically were prospectively included, and in this cohort other diagnoses than glioma could occur. Clinical, radiological and molecular data were collected. For clinical evaluation we included all patients with IDH-mut astrocytomas. In the 2010-2016 cohort DNA methylation analysis with Infinium MethylationEPIC BeadChip (Illumina) was performed for patients with an IDH-mut astrocytoma with available tissue. We aimed to examine the association of the T2-FLAIR mismatch sign with clinical factors and outcomes. Additionally, we evaluated the diagnostic reliability of the mismatch sign and its relation to methylation profiles.Out of 215 patients with LGG, 135 had known IDH-mutation and 1p19q codeletion status. Fifty patients had an IDH-mut astrocytoma and 12 of these (24.0%) showed a mismatch sign. The sensitivity and specificity of the mismatch sign for IDH-mut detection were 26.4 and 97.6%, respectively. There were no differences between patients with an IDH-mut astrocytoma with or without mismatch sign when grouped according to T2-FLAIR mismatch sign with respect to baseline characteristics, clinical outcomes and methylation profiles. The overall interrater agreement between neuroradiologist and clinical neurosurgeons for the T2-FLAIR mismatch sign was significant when all 215 MRI examination assessed (κ = 0.77, p < 0.001, N = 215).The T2-FLAIR mismatch sign in patients with an IDH-mut astrocytoma is not associated with clinical presentation or outcome. It seems unlikely that the IDH-mut astrocytomas with mismatch sign represent a specific subentity. Finally, we have validated that the T2-FLAIR mismatch sign is a reliable and specific marker of IDH-mut astrocytomas.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?